Predilife S.A. (FRA:0GA)

Market Cap	4.38M -63.5%
Revenue (ttm)	835.81K +69.5%
Net Income	-3.93M
EPS	-1.00
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.9900
Previous Close	0.9900
Day's Range	0.9900 - 0.9900
52-Week Range	0.8300 - 3.4800
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 15, 2026

About Predilife

Predilife S.A. designs and markets predictive tests for the occurrence of serious illnesses. The company provides breast cancer predictive assessment; multi-pathology predictive assessment; and the Care4Eat solution, a nutrition assessment that allows employees to take stock of their eating habits and benefit from rebalancing and personalized advice. It also offers MammoRisk, a breast cancer prediction test based on the patient’s individual risk; and DenSeeMammo, a breast density measurement software. Predilife S.A. was incorporated in 2004 and...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2004
• Employees: 21
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 0GA

Financial Performance

In 2025, Predilife's revenue was 835,809, an increase of 69.47% compared to the previous year's 493,202. Losses were -3.93 million, -7.74% less than in 2024.

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error